Sign In
Buy NBRV
$1.42
+0 (+0%)
At Close: Nov 24, 2023
- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support
Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript
12:53am, Monday, 09'th Nov 2020
Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript
Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
04:01pm, Thursday, 05'th Nov 2020
-Relaunch of Xenleta® and Sivextro® commenced in late September-
Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
04:01pm, Monday, 02'nd Nov 2020
DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag
Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
08:01pm, Thursday, 06'th Aug 2020
-SIVEXTRO® adds revenue generating product creating additional scale and synergies- -Relaunch of XENLETA® and SIVEXTRO planned with targeted in-person promotion- -Conference call today at 4:30 p.m.
Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020
11:00am, Monday, 03'rd Aug 2020
DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag
Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
08:01pm, Thursday, 30'th Jul 2020
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag
Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?
02:21pm, Wednesday, 29'th Jul 2020
Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)
02:02pm, Tuesday, 28'th Jul 2020
-XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment op
Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study
11:00am, Thursday, 23'rd Jul 2020
-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone -Nabriva awarded grant funding from the Austrian Research Promotion Agency to further characterize the a
Analyst Sees 60% Upside for Nabriva (NBRV) Following Merck Deal
03:12pm, Friday, 17'th Jul 2020
As a general rule, when you hear about a tiny biotech "partnering" with a Big Pharma giant to market a drug, it's the smaller company that's doing all the work -- and the larger company that's providi
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) * AC Immune SA (NASDAQ: ACIU) ( announced clinical t
XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia
08:04pm, Thursday, 16'th Jul 2020
DUBLIN, Ireland, July 16, 2020 -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative.
Nabriva Soars on Agreement With Merck to Distribute Sivextro
04:00pm, Thursday, 16'th Jul 2020
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.
08:01pm, Wednesday, 15'th Jul 2020
Accretive transaction creates synergies and scale that strengthen Nabriva’s community-focused commercialization organization to optimize product uptake Nabriva partners with.
